Life sciences & healthcare legal cluster: Hub · Dawn raid · VBP · Hospital AR · Exclusive agency · HGR · Trial injury · CRO/CDMO · Device liability · Labeling · SaMD · Patent linkage · License · FDA WL · MDR/IVDR · Internet hospital · Trade secrets · Pharma ads · Device distribution · Sources · Checklist
Who may be in the frame
- Sponsor — protocol design, product risk, insurance arrangement, oversight of CRO.
- Site / hospital — standard of care, emergency response, medical records integrity.
- PI and study team — protocol adherence, consent conversations, eligibility deviations.
- CRO — monitoring failures, data issues, safety reporting delays (see CRO/CDMO disputes).
Compensation & “no-fault” style expectations
China clinical practice emphasises timely subject protection and compensation arrangements tied to trial insurance and ethics commitments—not a pure US-style litigation-first model. Still, fault narratives matter when injuries stem from protocol violations, manufacturing defects, or informed-consent failures. Draft interfaces among: insurance policy triggers, ethics committee undertakings, clinical trial agreements (CTA), and subject-facing compensation language.
Trial insurance claim disputes
- Causation fights: underlying disease vs trial intervention vs hospital care.
- Notification and cooperation clauses missed by sites—claims denied on process.
- Coverage territory and “experimental injury” definitions that do not match protocol amendments.
- Subrogation and who controls defence when subject sues hospital and names sponsor.
Informed consent (ICF) defects
ICF problems are both ethics and litigation fuel: incomplete risk language, poor readability, missing alternatives, or consent obtained under therapeutic misconception. After an SAE, preserve the signed ICF version, consent process notes, and any re-consent history. Related integrity issues: data fraud red line.
PI error vs sponsor design risk
Eligibility deviations and dosing errors look like site fault; under-disclosed known risks or defective product lots look like sponsor/manufacturer fault. Early joint reviews should avoid blame emails that become exhibits. Use a structured privilege-aware investigation protocol with PRC counsel.
Immediate response checklist
- Subject care first; document clinical decisions.
- SAE/SUSAR reporting clocks—do not let legal review freeze safety reporting.
- Hold relevant product lots; pull chain-of-custody and temperature logs.
- Notify insurers within policy windows.
- Align public/hospital communications; no speculative fault admissions by junior staff.
Related
HGR · Clinical data cross-border · Hub
Need sector counsel?
Map your issue to a specialty desk: Life sciences & healthcare · Devices & IVD · Clinical & health data · Product liability · Industry hub.
Find counsel
